Linden Thomas Advisory Services LLC Buys 2,152 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Linden Thomas Advisory Services LLC raised its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 7.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 30,975 shares of the biopharmaceutical company’s stock after purchasing an additional 2,152 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Royalty Pharma were worth $870,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. CWM LLC grew its position in shares of Royalty Pharma by 75.9% in the 3rd quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 2,064 shares during the period. Handelsbanken Fonder AB increased its holdings in Royalty Pharma by 17.7% during the 3rd quarter. Handelsbanken Fonder AB now owns 931,636 shares of the biopharmaceutical company’s stock worth $25,285,000 after purchasing an additional 140,300 shares in the last quarter. Ridgewood Investments LLC raised its position in Royalty Pharma by 19.8% in the 3rd quarter. Ridgewood Investments LLC now owns 25,787 shares of the biopharmaceutical company’s stock valued at $700,000 after buying an additional 4,267 shares during the last quarter. Xponance Inc. grew its position in Royalty Pharma by 38.8% in the third quarter. Xponance Inc. now owns 18,218 shares of the biopharmaceutical company’s stock valued at $494,000 after purchasing an additional 5,090 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Royalty Pharma by 75.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 209,576 shares of the biopharmaceutical company’s stock valued at $5,612,000 after acquiring an additional 90,282 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on RPRX. JPMorgan Chase & Co. decreased their target price on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, February 20th. The Goldman Sachs Group decreased their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. Bank of America lowered their price objective on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Thursday, April 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average price target of $46.75.

Royalty Pharma Trading Up 0.5 %

NASDAQ RPRX opened at $28.11 on Friday. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.61. The business has a fifty day simple moving average of $29.65 and a 200 day simple moving average of $28.54. Royalty Pharma plc has a 12 month low of $25.92 and a 12 month high of $35.76. The firm has a market capitalization of $16.79 billion, a P/E ratio of 14.87 and a beta of 0.45.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.12. The company had revenue of $736.00 million for the quarter, compared to analyst estimates of $702.90 million. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. On average, analysts predict that Royalty Pharma plc will post 3.95 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend is Thursday, May 16th. Royalty Pharma’s payout ratio is 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.